Nanobiotix’s Nanoparticle Technology Shows Tumor-Killing Effect in Early-Stage Head & Neck Cancer
Nanobiotix (NASDAQ:NBTX), ahead of the 2021 Annual Meeting of the American Society for Clinical Oncology meeting, has said that…
Alkermes Says Presents New Data On Nemvaleukin Alfa At 2021 ASCO Meeting
Alkermes plc (NASDAQ:ALKS) today announced new data from its ARTISTRY clinical development program for nemvaleukin alfa (nemvaleukin), Alkermes' novel, investigational engineered interleukin-2 (IL-2)
Puma Biotech Highlights Presentation Of Data From Phase 3 ExteNET Trial In Early Stage HER2-Positive Breast Cancer Patients At American Society Of Clinical Oncology
Results show improved outcomes in overall survival in patients with HER2-positive early stage breast cancer who received ≥ 11 months of treatment with neratinib
LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc.
Puma Biotech Highlights Presentation Of Data Comparing Findings From Phase 2 CONTROL Trial With Neratinib Arm Of Phase 3 ExteNET Trial At American Society of Clinical Oncology
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, presented results at the virtual 2021 ASCO Annual Meeting comparing the diarrhea mitigation strategies investigated in the Phase II CONTROL trial with
Agenus Says Co’s Presentations At ASCO 2021 ‘Demonstrate Differentiated Activity of Balstilimab and Provide Clinical Update on AGEN2373’
Agenus (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections,
BeiGene Presents Clinical Data From 2 Phase 2 Trials Of Pamiparib At 2021 ASCO Meeting
Pamiparib, a potent and selective PARP1 and PARP2 inhibitor, demonstrated meaningful and durable efficacy in patients with advanced HER2-negative breast cancer
Pamiparib showed numerically higher progression-free
Y-mAbs Highlights Frontline Data For DANYELZA In High-Risk Neuroblastoma To Be Presented At American Society of Clinical Oncology Jun. 4
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (NASDAQ:YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based
Allogene Therapeutics Highlights Phase 1 Data On ALLO-501 And ALLO-501A In Relapsed/Refractory Non-Hodgkin Lymphoma At 2021 ASCO Meeting
ASCO Posters Detail Results from ALLO-501 ALPHA and ALLO-501A ALPHA2 Trials in Non-Hodgkin Lymphoma and Safety and PK/PD Data of ALLO-647 with Flu/Cy Across the ALPHA, ALPHA2 and UNIVERSAL Studies
Results from
Athenex Highlights Data For 2 Poster Presentations At American Society Of Clinical Oncology
Data from oral docetaxel phase I pharmacokinetic study shows oral administration can achieve exposure comparable to IV docetaxel
Post-hoc subgroup efficacy analysis based on updated tumor subtypes in the oral